Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szu-Chun Yang

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2025
Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung CancerXiao Wang, Do H Lee, Szu-Chun Yang, et al.
BMJ Open|March 10, 2023
Estimating time and transportation costs associated with lung cancer screening and diagnostic lung procedures in Taiwan: a cross-sectional survey in a medical centreChi-Hao Wu, Li-Jung Elizabeth Ku, Chien-Yu Lin, et al.
Oncotarget|January 19, 2017
Liquid biopsy genotyping in lung cancer: ready for clinical utility?Wei-Lun Huang, Yi-Lin Chen, Szu-Chun Yang, et al.
Respiratory Medicine|September 9, 2020
Life expectancy (LE) and loss-of-LE for patients with chronic obstructive pulmonary diseaseChiung-Zuei Chen, Chia-Yin Shih, Tzuen-Ren Hsiue, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|June 13, 2025
Validation of the Test of Adherence to Inhalers (TAI) among Taiwanese Patients with Chronic Obstructive Pulmonary DiseaseYin-Han Wang, Tsung-Ming Yang, Tien-Pei Fang, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte RatioJeng-Shiuan Tsai, Sheng-Huan Wei, Chian-Wei Chen, et al.
BMC Cancer|December 7, 2013
Estimating the lifelong health impact and financial burdens of different types of lung cancerSzu-Chun Yang, Wu-Wei Lai, Wu-Chou Su, et al.
Therapeutic Advances in Medical Oncology|September 29, 2018
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancerPo-Lan Su, Yi-Lin Wu, Wei-Yuan Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 18, 2021
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysisJeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, et al.
Thoracic Cancer|November 20, 2021
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitorsSheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2025
Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung CancerXiao Wang, Do H Lee, Szu-Chun Yang, et al.
BMJ Open|March 10, 2023
Estimating time and transportation costs associated with lung cancer screening and diagnostic lung procedures in Taiwan: a cross-sectional survey in a medical centreChi-Hao Wu, Li-Jung Elizabeth Ku, Chien-Yu Lin, et al.
Oncotarget|January 19, 2017
Liquid biopsy genotyping in lung cancer: ready for clinical utility?Wei-Lun Huang, Yi-Lin Chen, Szu-Chun Yang, et al.
Respiratory Medicine|September 9, 2020
Life expectancy (LE) and loss-of-LE for patients with chronic obstructive pulmonary diseaseChiung-Zuei Chen, Chia-Yin Shih, Tzuen-Ren Hsiue, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|June 13, 2025
Validation of the Test of Adherence to Inhalers (TAI) among Taiwanese Patients with Chronic Obstructive Pulmonary DiseaseYin-Han Wang, Tsung-Ming Yang, Tien-Pei Fang, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte RatioJeng-Shiuan Tsai, Sheng-Huan Wei, Chian-Wei Chen, et al.
BMC Cancer|December 7, 2013
Estimating the lifelong health impact and financial burdens of different types of lung cancerSzu-Chun Yang, Wu-Wei Lai, Wu-Chou Su, et al.
Therapeutic Advances in Medical Oncology|September 29, 2018
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancerPo-Lan Su, Yi-Lin Wu, Wei-Yuan Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 18, 2021
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysisJeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, et al.
Thoracic Cancer|November 20, 2021
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitorsSheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, et al.
Pageof 6